STUDY OF MOLECULAR-GENETIC FEATURES METACHRONOUS BREAST CANCER

Аннотация

Objective: to study the level of tumor markers and the frequency of mutations in the BRCA1/2 genes in metachronous breast cancer (BC). Methods: In 58 patients with BC with II-III clinical stages of the disease and metachronous oncogynecological tumors, the level of tumor markers and mutations in the BRCA1/2 genes were studied. Results: ELISA analysis of the level of tumor markers in patients with BC showed that in the development of metachronous cancer, the studied markers were more common than in the control group. At the same time, an excess of levels significant for diagnosis was observed for CA-125, CA-15-3 and CA-19-9 in both groups of patients, but in the group of patients with BC with metachronous tumors, these indicators were above the norm by an average of 2-3 times . The total frequency of occurrence of patients with clinically significant germline mutations in the BRCA1/2 genes in the control group was 5 (15.6%), while this figure occurred in 16 (61.5%) patients with BC with metachronous tumors. Conclusions. Dynamic study of the level of tumor markers CA-125 and CA-15-3 and CA-19-9 may be useful in the preventive examination of patients with a history of BC as an early diagnosis of the development of metachronous tumors in them. The most important diagnostic unfavorable factor in the development of metachronous tumors in BC patients was germline mutations in the BRCA1/2 genes.